Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

What's fueling the biotech engine—2012 to 2013

Nature Biotechnology volume 32, pages 32–39 (2014)Cite this article

Subjects

Biologics sales grew at an incredible rate during the past 18 months, especially when compared with pharmaceuticals. But with pressure on pricing and biosimilars looming, how long will it be until biologics' last hurrah?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Top nine categories of biologic drugs in terms of US sales in 2012.
Figure 3: Top companies with the majority of sales of biologic drugs in 2012.
Figure 4: Trends in US sales of mAbs.
Figure 5: Trends in US sales of recombinant hormones.
Figure 6: Trends in US sales of growth factors.
Figure 7: US sales of fusion proteins ($ billions).
Figure 8: US sales of cytokines and therapeutic enzymes ($ billions).
Figure 9: US sales of blood factors and recombinant vaccines ($ billions).

References

  1. Anonymous. Biosimilar legislation state by state. Nat. Biotechnol. 31, 947 (2013).

  2. Aggarwal, S. What's fueling the biotech engine? Nat. Biotechnol. 25, 1097–1104 (2007).

    Article  CAS  Google Scholar 

  3. Aggarwal, S. What's fueling the biotech engine—2009 to 2010. Nat. Biotechnol. 28, 1165–1171 (2010).

    Article  CAS  Google Scholar 

  4. Aggarwal, S. What's fueling the biotech engine—2010 to 2011. Nat. Biotechnol. 29, 1083–1089 (2011).

    Article  CAS  Google Scholar 

  5. Aggarwal, S.R. What's fueling the biotech engine—2011 to 2012. Nat. Biotechnol. 30, 1191–1197 (2012).

    Article  CAS  Google Scholar 

  6. Aggarwal, S. What's fueling the biotech engine—2008. Nat. Biotechnol. 27, 987–993 (2009).

    Article  CAS  Google Scholar 

  7. Aggarwal, S. What's fueling the biotech engine—2007. Nat. Biotechnol. 26, 1227–1233 (2008).

    Article  CAS  Google Scholar 

  8. Anonymous. Building a wall against biosimilars. Nat. Biotechnol. 31, 264 (2013).

  9. Anonymous. Bevacizumab is the first agent to significantly improve survival in recurrent cervical cancer. ASCO Daily News (4 June 2013).

  10. Gabay, C. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381, 1541–1550 (2013).

    Article  CAS  Google Scholar 

  11. Griffiths, C.E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118–128 (2010).

    Article  CAS  Google Scholar 

  12. Fellner, C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. PT 37, 503–530 (2012).

    Google Scholar 

  13. Fox, J.L. Anthrax drug first antibacterial mAb to win approval. Nat. Biotechnol. 31, 8 (2013).

    Article  CAS  Google Scholar 

  14. Pratley, R.E. et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375, 1447–1456 (2010).

    Article  CAS  Google Scholar 

  15. Volovat, C. et al. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. Clin. Breast Cancer (in the press) (2013).

  16. Bach, P.B., Saltz, L.B. & Wittes, R.E. In cancer care, cost matters. The New York Times (12 October 2012).

  17. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121, 4439–4442 (2013).

  18. Powell, J.S. et al. Phase 3 Study of recombinant factor IX Fc fusion protein in hemophilia B. N. Engl. J. Med. doi:10.1056/NEJMoa1305074 (4 December 2013).

  19. Anonymous. Failure to launch. Nat. Biotechnol. 31, 1 (2013).

  20. Novel Health Strategies United States Health Care Reform Act 2014-2020, (2013).

Download references

Acknowledgements

The author thanks Novel Health Strategies, the Institute for Global Policy Research, the American Society of Clinical Oncology, the American College of Rheumatology, the American Association of Liver Diseases, American Heart Association, the American Society of Hematology and the Biotechnology Industry Association for providing support for this article.

Author information

Authors and Affiliations

  1. Saurabh (Rob) Aggarwal is at Novel Health Strategies LLC, Bethesda, Maryland, USA, and the Institute for Global Policy Research, Washington, DC, USA.,

    Saurabh (Rob) Aggarwal

Authors
  1. Saurabh (Rob) Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saurabh (Rob) Aggarwal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

(Rob) Aggarwal, S. What's fueling the biotech engine—2012 to 2013. Nat Biotechnol 32, 32–39 (2014). https://doi.org/10.1038/nbt.2794

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2794

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research